Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Cancer Combination Fails In Phase III
Executive Summary
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.